Abstract
Analyses of in vitro and patient-derived in vivo models of breast cancer reveal that a combination of inhibitors of the enzymes PARP and phosphoinositide 3-kinase (PI3K) is a potentially effective treatment regimen for breast cancer tumors with elevated activity of the PI3K pathway.
©2012 AACR.
Publication types
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Animals
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
-
BRCA1 Protein / biosynthesis*
-
BRCA2 Protein / biosynthesis*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / enzymology*
-
Enzyme Inhibitors / therapeutic use*
-
Female
-
Genes, BRCA1*
-
Humans
-
Phosphoinositide-3 Kinase Inhibitors*
-
Poly(ADP-ribose) Polymerase Inhibitors*
Substances
-
BRCA1 Protein
-
BRCA2 Protein
-
Enzyme Inhibitors
-
Phosphoinositide-3 Kinase Inhibitors
-
Poly(ADP-ribose) Polymerase Inhibitors